Loading quotes...

Forecast

The analysts' average price target is €11.57 (+307.39%). The median is €11.57 (+307.39%).

Buy	16
Hold	0
Sell	0

News Go to news feed

Ardelyx aims for profitability in 2027 despite payers' cost pressure

At the Cantor Global Healthcare Conference, Ardelyx confirmed it remains on track to become profitable in 2027, supported by stronger product margins and revenue growth. IBSRELA generated $274 million in revenues in 2024 and is expected to reach $350–370 million in 2025, while XPHOZAH is forecast to remain at $110–120 million for 2025 and paid prescriptions recently rose by 25%. Payers have introduced step-therapy mandates and stricter authorization rules, prompting Ardelyx to increase its reimbursement team and launch digital direct-to-consumer advertising. The company has $282 million in cash, emphasizes patent protection for IBSRELA through 2042, and expects Phase III results for a CIC study in 2026. » More on de.investing.com
Ardelyx stock plunges 18%; put trading explodes

Ardelyx stock fell 18.4% on Friday to $3.98. Options activity rose to 11,147 contracts, of which 10,676 were puts; 10,004 contracts were for a put expiring October 16, 2026 with a $4 strike. The 3‑month volatility climbed to 74.93% and the 3‑month skew increased markedly, suggesting heightened hedging or speculative short bets. » More on de.investing.com
Ardelyx cuts outlook for IBSRELA and withdraws XPHOZAH target, stock plunges after Q2 results

Ardelyx reported record product revenue in Q2 of $118 million (+31% year-on-year), but management lowered the full-year forecast for IBSRELA to $350–370 million and withdrew the previous sales target for XPHOZAH. The company cited tightened payer access restrictions and uncertainty after the end of TDAPA, which is slowing the growth of new patients. The stock fell about 18% in after-hours trading to $3.99 despite improved loss figures and a continued expectation of profitability in 2027. » More on de.investing.com

Financials

In the last quarter, Ardelyx had revenue of €105.91m and net profit of -€14.65m

(EUR)	June 2026	YoY
Revenue	105.91m	27.82%
Gross profit	100.87m	40.48%
Net profit	-14.65m	9.49%
EBITDA	-9.68m	3.88%

Fundamentals

Metric	Value
Market capitalization	€671.75m
Number of shares	249.19m
52-week high/low	€7.47 - €2.63
Dividends	No
Beta	0.68
P/E ratio	-13.42
PEG ratio	5.47
P/B ratio	5.04
P/S ratio	1.67

Company profile

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.